• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Accomplishments in 2007 in the treatment of metastatic pancreatic cancer.2007年转移性胰腺癌治疗方面的成就。
Gastrointest Cancer Res. 2008 May;2(3 Suppl):S37-41.
2
Accomplishments in 2007 in the adjuvant treatment of rectal cancer.2007年直肠癌辅助治疗的成果。
Gastrointest Cancer Res. 2008 May;2(3 Suppl):S7-S12.
3
Accomplishments in 2007 in the management of curable metastatic colorectal cancer.2007年可治愈转移性结直肠癌的管理成就
Gastrointest Cancer Res. 2008 May;2(3 Suppl):S13-8.
4
Accomplishments in 2007 in the management of localized pancreatic cancer.2007年局部胰腺癌管理方面的成就。
Gastrointest Cancer Res. 2008 May;2(3 Suppl):S32-6.
5
Accomplishments in 2007 in the management of advanced gastroesophageal cancer.2007年晚期胃食管癌管理方面的成就。
Gastrointest Cancer Res. 2008 May;2(3 Suppl):S47-50.
6
Accomplishments in 2008 in the management of advanced gastroesophageal cancer.2008年晚期胃食管癌管理方面的成就。
Gastrointest Cancer Res. 2009 Sep;3(5 Supplement 2):S58-61.
7
Accomplishments in 2007 in the management of localized gastric cancer.2007年局部胃癌管理方面的成就。
Gastrointest Cancer Res. 2008 May;2(3 Suppl):S42-6.
8
Accomplishments in 2007 in the adjuvant treatment of colorectal cancer.2007年结直肠癌辅助治疗的成果。
Gastrointest Cancer Res. 2008 May;2(3 Suppl):S2-6.
9
Accomplishments in 2008 in the adjuvant treatment of colon cancer.2008年结肠癌辅助治疗的成果。
Gastrointest Cancer Res. 2009 Sep;3(5 Supplement 2):S2-7.
10
Accomplishments in 2007 in the management of hepatobiliary cancers.2007年肝胆癌管理方面的成就。
Gastrointest Cancer Res. 2008 May;2(3 Suppl):S25-31.

引用本文的文献

1
Oncologic resection of pancreatic cancer with isolated liver metastasis: Favorable outcomes in select patients.胰腺癌伴孤立性肝转移的肿瘤切除术：选择患者的有利结果。
J Hepatobiliary Pancreat Sci. 2023 Aug;30(8):1025-1035. doi: 10.1002/jhbp.1303. Epub 2023 Feb 7.
2
Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinoma.分析新型免疫检查点 Siglec-15 在胰腺导管腺癌中的作用。
J Pathol Clin Res. 2022 May;8(3):268-278. doi: 10.1002/cjp2.260. Epub 2022 Jan 27.
3
Oligometastatic Pancreatic Cancer to the Liver in the Era of Neoadjuvant Chemotherapy: Which Role for Conversion Surgery? A Systematic Review and Meta-Analysis.新辅助化疗时代寡转移胰腺癌肝转移：转化手术的作用是什么？一项系统评价和荟萃分析
Cancers (Basel). 2020 Nov 17;12(11):3402. doi: 10.3390/cancers12113402.
4
Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer.组织蛋白酶D在胰腺癌中的表达与吉西他滨耐药性
JNCI Cancer Spectr. 2019 Aug 16;4(1):pkz060. doi: 10.1093/jncics/pkz060. eCollection 2020 Feb.
5
Downregulation of miR-183 inhibits the growth of PANC-1 pancreatic cancer cells and , and increases chemosensitivity to 5-fluorouracil and gemcitabine.miR-183的下调抑制了PANC-1胰腺癌细胞的生长，并增加了对5-氟尿嘧啶和吉西他滨的化疗敏感性。
Exp Ther Med. 2019 Mar;17(3):1697-1705. doi: 10.3892/etm.2018.7112. Epub 2018 Dec 19.
6
Survival of Patients with Oligometastatic Pancreatic Ductal Adenocarcinoma Treated with Combined Modality Treatment Including Surgical Resection: A Pilot Study.接受包括手术切除在内的综合治疗的寡转移胰腺导管腺癌患者的生存情况：一项前瞻性研究。
J Pancreat Cancer. 2018 Nov 1;4(1):88-94. doi: 10.1089/pancan.2018.0011. eCollection 2018.
7
[Oligometastasis in pancreatic cancer : Current state of knowledge and spectrum of local therapy].[胰腺癌寡转移：当前知识现状与局部治疗范围]
Chirurg. 2018 Jul;89(7):510-515. doi: 10.1007/s00104-018-0626-1.
8
Advanced EUS Guided Tissue Acquisition Methods for Pancreatic Cancer.胰腺癌的先进超声内镜引导下组织获取方法
Cancers (Basel). 2018 Feb 17;10(2):54. doi: 10.3390/cancers10020054.
9
Portal vein resection and reconstruction with artificial blood vessels is safe and feasible for pancreatic ductal adenocarcinoma patients with portal vein involvement: Chinese center experience.对于门静脉受累的胰腺导管腺癌患者，采用人工血管进行门静脉切除和重建是安全可行的：中国中心经验。
Oncotarget. 2017 Sep 12;8(44):77883-77896. doi: 10.18632/oncotarget.20847. eCollection 2017 Sep 29.
10
Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability.伴有同步肝转移的胰腺导管腺癌的术前评估：不可切除性的诊断与评估
World J Gastroenterol. 2016 Dec 7;22(45):10024-10037. doi: 10.3748/wjg.v22.i45.10024.

本文引用的文献

1
Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice.晚期胰腺癌的二线化疗：意大利南部肿瘤协作组关于FOLFOX4方案在临床实践中的活性和安全性的多中心调查。
Ann Oncol. 2007 Jun;18 Suppl 6:vi124-7. doi: 10.1093/annonc/mdm240.
2
Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials.基于吉西他滨的联合方案治疗不可切除胰腺癌：我们真的取得进展了吗？一项对20项3期试验的荟萃分析
Cancer. 2007 Aug 1;110(3):525-33. doi: 10.1002/cncr.22809.
3
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.局部晚期和转移性胰腺癌化疗的荟萃分析。
J Clin Oncol. 2007 Jun 20;25(18):2607-15. doi: 10.1200/JCO.2006.09.2551.
4
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.吉西他滨联合卡培他滨与单用吉西他滨治疗晚期胰腺癌的比较：瑞士临床癌症研究组和中欧肿瘤协作组的一项随机、多中心、III期试验
J Clin Oncol. 2007 Jun 1;25(16):2212-7. doi: 10.1200/JCO.2006.09.0886.
5
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.厄洛替尼联合吉西他滨与吉西他滨单药治疗晚期胰腺癌患者的比较：加拿大国家癌症研究所临床试验组的一项III期试验
J Clin Oncol. 2007 May 20;25(15):1960-6. doi: 10.1200/JCO.2006.07.9525. Epub 2007 Apr 23.
6
Identification of pancreatic cancer stem cells.胰腺癌干细胞的鉴定。
Cancer Res. 2007 Feb 1;67(3):1030-7. doi: 10.1158/0008-5472.CAN-06-2030.

2007年转移性胰腺癌治疗方面的成就。

Accomplishments in 2007 in the treatment of metastatic pancreatic cancer.

作者信息

Louvet Christophe, Philip Philip A

机构信息

Professor of Medicine, Department of Medical Oncology, Hôpital St. Antoine, Paris, France.

出版信息

Gastrointest Cancer Res. 2008 May;2(3 Suppl):S37-41.

PMID:19352467
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2664908/
Abstract

Overview of the Disease IncidencePrognosisCurrent Therapy Standards ChemotherapyAccomplishments and Lack of Accomplishments During the Year TherapyBiomarkersBasic ScienceWhat Needs To Be Done (Application of the Accomplishments) Controversies and Disagreements When To Transition to a Phase III Study?What is the Optimum Design for Pilot Studies?Future Directions Comments on ResearchHow To Capture Data From Preclinical Research?Obstacles to ProgressConclusions.

摘要

疾病发病率概述

预后

当前治疗标准 化疗

本年度治疗的成就与不足

生物标志物

基础科学

需要做的事情（成就的应用）

争议与分歧

何时过渡到III期研究？

初步研究的最佳设计是什么？

未来方向 对研究的评论

如何从临床前研究中获取数据？

进展的障碍

结论